Erratum: Correction to Fragment-Based Discovery of Indole Inhibitors of Matrix Metalloproteinase-13 (Journal of Medicinal Chemistry (2011) 54 (8174-8187) DOI: 10.1021/jm201129m);Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13

Journal of Medicinal Chemistry

Volumn 54, Issue 23, 2011, Pages 8174-8187

  Taylor, Steven J ^a   Abeywardane, Asitha ^a   Liang, Shuang ^a   Muegge, Ingo ^a   Padyana, Anil K ^a   Xiong, Zhaoming ^a   Hill Drzewi, Melissa ^a   Farmer, Bennett ^a   Li, Xiang ^a   Collins, Brandon ^a   Li, John Xiang ^a   Heim Riether, Alexander ^a   Proudfoot, John ^a   Zhang, Qiang ^a   Goldberg, Daniel ^b   Zuvela Jelaska, Ljiljana ^a   Zaher, Hani ^c   Li, Jun ^a   Farrow, Neil A ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b Karos Pharmaceuticals   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1H INDOLE 2,5 DICARBOXYLIC ACID 5 AMIDE 2 ETHYLAMIDE; 2 BUTYRYL 1H INDOLE 5 CARBOXYLIC ACID AMIDE; 4 ([[5 (1H INDOL 5 YL) 1 METHYL 1H PYRAZOLE 3 CARBONYL]AMINO]METHYL)BEZOIC ACID; 4 ([[5 (20 ETHOXYMETHYL 1H INDOL 5 YL) 1 METHYL 1H PYRAZOLE 3 CARBONYL]AMINO]METHYL)BEZOIC ACID; 5 (2 ETHOXYCARBONYL 1H INDEN 5 YL) 1 METHYL 1H PYRAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 5 (3 METHYL PYRIDIN 4 YL) 1H INDOLE 2 CARBOXYLIC ACID ETHYL ESTER; 5 PHENYL 1H INDOLE 2 CARBOXYLIC ACID ETHYL ESTER; 5 PYRIDIN 2 YL 1H INDOLE 2 CARBOXYLIC ACID ETHYL ESTER; 5 PYRIDIN 3 YL 1H INDOLE 2 CARBOXYLIC ACID ETHYL ESTER; 5 PYRIDIN 4 YL 1H INDOLE 2 CARBOXYLIC ACID ETHYL ESTER; 5 [2 METHYL 5 [(6 OXO 1,6 DIHYDRO PYRIDIN 3 YLMETHYL)CARBAMOYL] 2H PYRAZOL 3 YL] 1H INDOLE 2 CARBOXYLIC ACID ETHYL ESTER; 5 [2 METHYL 5 [(PYRIDIN 4 YLMETHYL) CARBAMOYL] 2H PYRAZOL 3 YL] 1H INDOLE 2 CARBOXYLIC ACID ETHYL ESTER; 5 [5 (4 CARBOXY BENZYLCARBAMOYL) 2 METHYL 2H PYRAZOL 3 YL] 1H INDOLE 2 CARBOXYLIC; 5 [5 (4 CARBOXY BENZYLCARBAMOYL) 2 METHYL 2H PYRAZOL 3 YL] 1H INDOLE 2 CARBOXYLIC ACID ETHYL ESTER; 5 [5 (4 CARBOXYMETHYL BENZYLCARBAMOYL) 2 METHYL 2H PYRAZOL 3 YL] 1H INDOLE 2 CARBOXYLIC ACID ETHYL ESTER; 5 [5 METHYL 2 [(PYRIDIN 4 YLMETHYL)CARBAMOYL]PYRIDIN 4 YL] 1H INDOLE 2 CARBOXYLIC ACID ETHYL ESTER; AMIDE; COLLAGENASE 3; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; X RAY CRYSTALLOGRAPHY;

EID: 82555187389     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00962     Document Type: Erratum

References (39)

1. Eitner, K.; Koch, U. From fragment screening to potent binders: strategies for fragment-to-lead evolution Mini Rev. Med. Chem. 2009, 9, 956-961
2. Schulz, M. N.; Hubbard, R. E. Recent progress in fragment-based lead discovery Curr. Opin. Pharmacol. 2009, 9, 615-621
3. Mayr, L. M.; Bojanic, D. Novel trends in high-throughput screening Curr. Opin. Pharmacol. 2009, 9, 580-5888
4. Bembenek, S. D.; Tounge, B. A.; Reynolds, C. H. Ligand efficiency and fragment-based drug discovery Drug Discovery Today 2009, 14, 278-283
5. Jacoby, E.; Davies, J.; Blommers, M. J. Design of small molecule libraries for NMR screening and other applications in drug discovery Curr. Top. Med. Chem. 2003, 3, 11-23
6. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR Science 1996, 274, 1531-1542
7. Hajduk, P. J.; Sheppard, G.; Nettesheim, D. G.; Olejniczak, E. T.; Shuker, S. B.; Meadows, R. P.; Steinman, D. H.; Carrera, G. M., Jr.; Marcotte, P. A; Severin, J.; Walter, K.; Smith, H.; Gubbins, E.; Simmer, R.; Holzman, T. F.; Morgan, D. W.; Davidsen, S. K.; Summers, J. B.; Fesik, S. W. Discovery of potent nonpeptide inhibitors of stromelysinusing SAR by NMR J. Am. Chem. Soc. 1997, 119, 5818-5827
8. Fejzo, J.; Lepre, C. A.; Peng, J. W.; Bemis, G. W.; Murcko, M. A.; Moore, J. M. The SHAPES strategy: An NMR-based approach for lead generation in drug discovery Chem. Biol. 1999, 6, 755-769
9. Neumann, T.; Junker, H. D.; Schmidt, K.; Sekul, R. SPR-based fragment screening: Advantages and applications Curr. Top. Med. Chem. 2007, 7, 1630-1642
10. Recht, M. I.; De Bruyker, D.; Bell, A. G.; Wolkin, M. V.; Peeters, E.; Anderson, G. B.; Kolatkar, A. R.; Bern, M. W.; Kuhn, P.; Bruce, R. H.; Torres, F. E. Enthalpy array analysis of enzymatic and binding reactions Anal. Biochem. 2008, 377, 33-39
11. Alex, A. A.; Flocco, M. M. Fragment Based Drug Discovery Drug Discovery Today 2009, 13-14, 668-675
12. Chessari, G.; Woodhead, A. J. From fragment to clinical candidate-A historical perspective Curr. Top. Med. Chem. 2007, 7, 1544-1567
13. Morrison, C. J.; Butler, G. S.; Rodríguez, D.; Overall, C. M. Matrix metalloproteinase proteomics: substrates, targets, and therapy Curr. Opin. Cell Biol. 2009, 5, 645-653
14. Cudic, M.; Fields, G. B. Extracellular proteases as targets for drug development Curr. Protein Pept. Sci. 2009, 4, 297-307
15. Tu, G.; Xu, W.; Huang, H.; Li, S. Progress in the development of matrix metalloproteinase inhibitors Curr. Med. Chem. 2008, 15, 1388-1395
16. Fingleton, B. Matrix metalloproteinases as valid clinical targets Curr. Pharm. Des. 2007, 13, 333-346
17. Li, X.; Li, J. Recent advances in the development of MMPIs and APNIs based on the pyrrolidine platforms Mini Rev. Med. Chem. 2010, 9, 794-805
18. Woessner, J. F.; Nagase, H., Eds. Matrix Metalloproteinases and TIMPs; Oxford University Press: New York, 2000; pp 1-240.
19. Historically, MMP-1 and -14 were the postulated key players in causing MSS. However, the nonselective MMP-13 inhibitor CP-544439, which is inactive against MMP-1, has caused MSS in clinical trials: Reiter, L. A.; Freeman-Cook, K. D.; Jones, C. S.; Martinelli, G. J.; Antipas, A. S.; Berliner, M. A.; Datta, K.; Downs, J.; Eskra, J. D.; Forman, M. D.; Greer, E. M.; Guzman, R.; Hardink, J. R.; Janat, F.; Keene, N. F.; Laird, E. R.; Liras, J.; Lopresti-Morrow, L. L.; Mitchell, P. G.; Pandit, J.; Robertson, D.; Sperger, D.; Vaughn-Bowser, M. L.; Waller, D. M.; Yocum, S. A. Potent, selective pyrimidinetrione-based inhibitors of MMP-13 Bioorg. Med. Chem. Lett. 2006, 5822-5826
20. Rowan, A. D.; Litherland, G. J.; Hui, W.; Milner, J. M. Metalloproteases as potential therapeutic targets in arthritis treatment Expert Opin. Ther. Targets 2008, 12, 1-18 and references therein.
21. Vincenti, M. P.; Brinckerhoff, C. E. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: Integration of complex signaling pathways for the recruitment of gene-specific transcription factors Arthritis Res. 2002, 4, 157-164
22. Tallant, C.; Marrero, A.; Gomis-Rüth, F. X. Matrix metalloproteinases: Fold and function of their catalytic domains Biochim. Biophys. Acta 2010, 1, 20-28
23. Jacobsen, J. A.; Major Jourden, J. L.; Miller, M. T.; Cohen, S. M. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition Biochim. Biophys. Acta 2010, 1, 72-94
24. Nuti, E.; Tuccinardi, T.; Rossello, A. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors Curr. Pharm. Des. 2007, 20, 2087-2100
25. Engel, C. K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K. U.; Wendt, K. U. Structural basis for the highly selective inhibition of MMP-13 Chem. Biol. 2005, 2, 181-189
26. Devel, L.; Czarny, B.; Beau, F.; Georgiadis, D.; Stura, E.; Dive, V. Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1′ cavity Biochimie 2010, 11, 1501-1508
27. Wu, J.; Rush, T. S., 3rd; Hotchandani, R.; Du, X.; Geck, M.; Collins, E.; Xu, Z. B.; Skotnicki, J.; Levin, J. I.; Lovering, F. E. Identification of potent and selective MMP-13 inhibitors Bioorg. Med. Chem. Lett. 2005, 18, 4105-4109
28. Monovich, L. G.; Tommasi, R. A.; Fujimoto, R. A.; Blancuzzi, V.; Clark, K.; Cornell, W. D.; Doti, R.; Doughty, J.; Fang, J.; Farley, D.; Fitt, J.; Ganu, V.; Goldberg, R.; Goldstein, R.; Lavoie, S.; Kulathila, R.; Macchia, W.; Parker, D. T.; Melton, R.; O'Byrne, E.; Pastor, G.; Pellas, T.; Quadros, E.; Reel, N.; Roland, D. M.; Sakane, Y.; Singh, H.; Skiles, J.; Somers, J.; Toscano, K.; Wigg, A.; Zhou, S.; Zhu, L.; Shieh, W. C.; Xue, S.; McQuire, L. W. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13 J. Med. Chem. 2009, 11, 3523-3538
29. Levin, J. I.; Chen, J. M.; Du, M. T.; Nelson, F. C.; Wehr, T.; DiJoseph, J. F.; Killar, L. M.; Skala, S.; Sung, A.; Sharr, M. A.; Roth, C. E.; Jin, G.; Cowling, R.; Di, L.; Sherman, M.; Xu, Z. B.; March, C. J.; Mohler, K. M.; Black, R. A.; Skotnicki, J. S. The discovery of anthranilic acid-based MMP inhibitors Bioorg. Med. Chem. Lett. 2001, 22, 2975-2978
30. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors Curr. Med. Chem. 2004, 11, 2911-2977
31. Rao, B. G. Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies Curr. Pharm. Des. 2005, 11, 295-322
32. Wasserman, Z. R. Making a new turn in matrix metalloprotease inhibition Chem. Biol. 2005, 2, 143-144
33. Engel, C. K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K. U.; Wendt, K. U. Structural Basis for the Highly Selective Inhibition of MMP-13 Chem. Biol. 2005, 12, 181-189
34. Klingler, O.; Kirsch, R.; Habermann, J.; Weithmann, K.-U.; Engel, C.; Pirard, B. Preparation of novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases. PCT Int. Appl. WO 2004041788, 2004. The crystal structure of the selective dicarboxamide pyrimidine MMP-13 inhibitor in complex with MMP-13 revealed a distinctive hydrogen-bonding network in the catalytic site. A structure-based virtual screening query was devised requiring hydrogen bonding to T245, T247, A238, and either to water 7 found in the cocrystal structure (PDB ID: 1XUD) or directly to M253. In addition, reaching either the S1′ or the S1′* pocket was required. Our internal compound collection was virtually screening against MMP-13 using Glide docking with constraints as described above yielding a hit set of approximately 15000 compounds. After clustering, visual inspection, and discarding structurally obvious analogues of known MMP-13 inhibitors, we chose 100 compounds to be tested for MMP-13 inhibition in a molecular assay.
35. Salemme, F. R.; Spurlino, J.; Bone, R. Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery Structure 1997, 3, 319-324
36. Heim-Riether, A.; Taylor, S. J.; Liang, S.; Gao, D. A.; Xiong, Z.; August, M. E.; Collins, B. K.; Farmer, B. T., 2nd; Haverty, K.; Hill-Drzewi, M.; Junker, H. D.; Margarit, M. S.; Moss, N.; Neumann, T.; Proudfoot, J. R.; Keenan, L. S.; Sekul, R.; Zhang, Q.; Li, J.; Farrow, N. A. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors Bioorg. Med. Chem. Lett. 2009, 18, 5321-5324
37. Gao, D. A.; Xiong, Z.; Heim-Riether, A.; Amodeo, L.; August, E. M.; Cao, X.; Ciccarelli, L.; Collins, B. K.; Harrington, K.; Haverty, K.; Hill-Drzewi, M; Li, X.; Liang, S.; Margarit, S. M.; Moss, N.; Nagaraja, N.; Proudfoot, J.; Roman, R.; Schlyer, S.; Keenan, L. S.; Taylor, S.; Wellenzohn, B.; Wiedenmayer, D.; Li, J.; Farrow, N. A. SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability Bioorg. Med. Chem. Lett. 2010, 17, 5039-5043
38. Boger, D. L. Preparation of CBI analogues of the duocarmycins and CC-1065 as antitumor agents with DNA alkylating activity. PCT Int. Appl. WO2004101767, 2004; 144.
39. Yasuma, T.; Ujikawa, O.; Iwata, H. Preparation of indoles and related compounds as glucokinase activators. PCT Int. Appl. WO2006112549, 2006; 379 pp.